Day : Wednesday

PALM INTRANET

Date: 3/16/2005
Time: 18:03:00

Inventor Name Search Result

Your Search was:

Last Name = ORLANDI
First Name = ALESSANDRA

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10148434	6713491	150	05/29/2002	HETEROCYCLIC DERIVATIVES	ORLANDI, ALESSANDRA
10775709	Not Issued	071	02/10/2004	HETEROCYCLIC DERIVATIVES	ORLANDI, ALESSANDRA

Inventor Search Completed: No Records to Display.

Search Another: Inventor **Last Name** orlandi **First Name** alessandra Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Uploading C:\Program Files\Stnexp\Queries\10775709.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 17:59:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L2 9 SEA SSS FUL L1

=> d l2 1-9

L2 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 476689-78-8 REGISTRY
CN D-Glucitol, 1-deoxy-1-(methylamino)-, (2R,4E)-7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-2-quinolinecarboxylate (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H17 Cl N2 O3 . C7 H17 N O5
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PRP (Properties)

CM 1

CRN 476689-77-7
CMF C20 H17 Cl N2 O3

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 476689-77-7 REGISTRY
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, (2R,4E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H17 Cl N2 O3
CI COM
SR CA

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 476689-76-6 REGISTRY
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt, (2R,4E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H17 Cl N2 O3 . Na
SR CA
LC STN Files: CA, CAPLUS, CASREACT
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)
CRN (476689-77-7)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



● Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 461053-65-6 REGISTRY
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H17 Cl N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 344436-92-6 REGISTRY
CN D-Glucitol, 1-deoxy-1-(methylamino)-, (4Z)-(-)-7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-2-quinolinecarboxylate (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, (4Z)-(-)-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1) (9CI)
FS STEREOSEARCH
MF C20 H17 Cl N2 O3 . C7 H17 N O5
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 252349-15-8
CMF C20 H17 Cl N2 O3

Rotation (-).
Double bond geometry as shown.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 252349-25-0 REGISTRY
CN 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)- (9CI) (CA INDEX NAME)
MF C20 H16 Cl2 N2 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 252349-17-0 REGISTRY
CN 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt (9CI) (CA INDEX NAME)
MF C20 H16 Cl2 N2 O3 . Na
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (252349-25-0)



● Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 252349-15-8 REGISTRY
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, (4Z)-(-)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H17 Cl N2 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Rotation (-).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 252349-09-0 REGISTRY
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt, (4Z)-(-)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H17 Cl N2 O3 . Na
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
CRN (252349-15-8)

Rotation (-).
Double bond geometry as shown.



● Na

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l2 and salt?
686714 SALT?
L3 5 L2 AND SALT?

=> File Caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.07	185.28

FILE 'CAPLUS' ENTERED AT 18:00:53 ON 16 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Mar 2005 VOL 142 ISS 12
FILE LAST UPDATED: 15 Mar 2005 (20050315/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:710135 CAPLUS
DOCUMENT NUMBER: 138:4509
TITLE: Novel Stereocontrolled Addition of Allylmetal Reagents

to α-Imino Esters: Efficient Synthesis of Chiral Tetrahydroquinoline Derivatives

AUTHOR(S): Di Fabio, Romano; Alvaro, Giuseppe; Bertani, Barbara; Donati, Daniele; Giacobbe, Simone; Marchioro, Carla; Palma, Carlotta; Lynn, Sean M.

CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline S.p.A, Verona, 37135, Italy

SOURCE: Journal of Organic Chemistry (2002), 67(21), 7319-7328
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:4509

GI



I



II

AB The sodium salts of tetrahydroquinolines I and II, antagonists of the glycine binding site of the NMDA receptor and potential agents for the treatment of chromic pain, are prepared diastereoselectively and enantioselectively on multigram scale using a stereoselective addition of an allyltrichlorostannane to an imine and a regioselective Heck arylation as the key steps. Chiral imines are prepared from (R)-tert-Bu lactate; the lactate ester acts as an effective chiral auxiliary for the addition of allyltrichlorostannane (prepared in situ from allyltributylstannane and tin tetrachloride) to the imines to provide nonracemic amino esters with the correct stereochem. for conversion to I and II. Ozonolysis of the allyl group and olefination with N-phenyloxodihydropyrrolylidene triphenylphosphorane gives an intermediate which undergoes Heck arylation followed by ester hydrolysis to provide the sodium salts of I and II. The selectivity of the Heck arylation is reversed by changes in the palladium catalyst and solvent; in the presence of palladium tetrakis(triphenylphosphine) and triethylamine in toluene, the exocyclic tetrasubstituted alkene leading to I is formed as the major product in a 96:4 ratio and 90% yield, while when palladium acetate and triethylamine are used as catalysts in DMF, the trisubstituted endocyclic alkene leading to II is prepared as the sole product in 70% yield. The crystal structure of an N-methylglucamine salt of I is determined by X-ray crystallog.

IT **476689-78-8**
RL: PRP (Properties)
(crystal structure; stereoselective and enantioselective preparation of tetrahydroquinolines using stereoselective addition of allylmetal reagents to α-imino esters containing lactate chiral auxiliaries and regioselective Heck arylations as key steps)

RN 476689-78-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, (2R,4E)-7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-2-quinolinecarboxylate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 476689-77-7
CMF C20 H17 Cl N2 O3

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



IT **476689-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective and enantioselective preparation of tetrahydroquinolines using stereoselective addition of allylmetal reagents to α-imino esters containing lactate chiral auxiliaries and regioselective Heck arylations as key steps)
RN 476689-76-6 CAPLUS
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt, (2R,4E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



● Na

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:435069 CAPLUS
DOCUMENT NUMBER: 135:51032
TITLE: Salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid
INVENTOR(S): Orlandi, Alessandra
PATENT ASSIGNEE(S): Glaxo Wellcome S.p.A., Italy
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042238	A1	20010614	WO 2000-EP12335	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393303	AA	20010614	CA 2000-2393303	20001207
BR 2000016235	A	20020827	BR 2000-16235	20001207
EP 1237886	A1	20020911	EP 2000-983240	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200201503	T2	20021021	TR 2002-200201503	20001207
TW 524804	B	20030321	TW 2000-89126096	20001207
JP 2003516403	T2	20030513	JP 2001-543537	20001207
AU 769232	B2	20040122	AU 2001-20060	20001207
AU 2001020060	A5	20010618		
US 2003008899	A1	20030109	US 2002-148434	20020529
US 6713491	B2	20040330		
ZA 2002004492	A	20040416	ZA 2002-4492	20020605
NO 2002002682	A	20020717	NO 2002-2682	20020606
US 2004162313	A1	20040819	US 2004-775709	20040210

PRIORITY APPLN. INFO.: GB 1999-29037 A 19991208
WO 2000-EP12335 W 20001207
US 2002-148434 A1 20020529

GI



I

AB The present invention relates to a novel salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid (I) or a solvate thereof, to processes for its preparation, to pharmaceutical compns. containing it and to its use in therapy and
in particularly its use as medicine for antagonizing the effects of excitatory amino acids upon the NMDA receptor complex. The (-)-meglumine salt of enantiomer A of I was prepared and pharmaceutical formulations containing this salt were prepared

IT **252349-09-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid)

RN 252349-09-0 CAPLUS

CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt, (4Z)-(-)- (9CI) (CA INDEX NAME)

Rotation (-).
Double bond geometry as shown.



● Na

IT **344436-92-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid)

RN 344436-92-6 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, (4Z)-(-)-7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-2-quinolinecarboxylate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 252349-15-8
CMF C20 H17 Cl N2 O3

Rotation (-).
Double bond geometry as shown.



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:795804 CAPLUS
DOCUMENT NUMBER: 132:35720
TITLE: Preparation of tetrahydroquinoline derivatives as glycine antagonists
INVENTOR(S): Di Fabio, Romano
PATENT ASSIGNEE(S): Glaxo Wellcome S.p.A., Italy
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964411	A1	19991216	WO 1999-EP3936	19990608

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2334727	AA	19991216	CA 1999-2334727	19990608
AU 9945092	A1	19991230	AU 1999-45092	19990608
AU 753867	B2	20021031		
BR 9911145	A	20010306	BR 1999-11145	19990608
EP 1086093	A1	20010328	EP 1999-927911	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200003652	T2	20010420	TR 2000-200003652	19990608
EE 200000733	A	20020617	EE 2000-733	19990608
JP 2002517492	T2	20020618	JP 2000-553420	19990608
NZ 508638	A	20030829	NZ 1999-508638	19990608
CZ 293605	B6	20040616	CZ 2000-4587	19990608
ZA 2000007225	A	20020306	ZA 2000-7225	20001206
NO 2000006227	A	20010208	NO 2000-6227	20001207
HR 2000000845	A1	20011031	HR 2000-845	20001208
BG 105123	A	20011130	BG 2001-105123	20010108
US 6362199	B1	20020326	US 2001-719188	20010215
US 2002052391	A1	20020502	US 2001-990513	20011116
US 6413985	B2	20020702		
US 2002169186	A1	20021114	US 2002-145258	20020514
US 6495566	B2	20021217		

PRIORITY APPLN. INFO.:	GB 1998-12408	A 19980610
	GB 1998-12410	A 19980610
	WO 1999-EP3936	W 19990608
	US 2001-719188	A1 20010215
	US 2001-990513	A1 20011116

OTHER SOURCE(S): MARPAT 132:35720

GI



I

AB The title compds. I [Y represents a carbon atom; Z is the group CH which is linked to the group Y via a double bond and X is CH or Z is methylene or NR11 and X is a carbon atom linked to the group Y via a double bond; A represents a C1-2 alkylene chain and which chain may be substituted by one or two groups selected from C1-6alkyl optionally substituted by hydroxy, amino, C1-4alkyl amino or C1-4dialkyl amino or which chain may be substituted by the group O; R represents a halogen atom or C1-4alkyl group; R1 represents a hydrogen, a halogen atom or C1-4alkyl group; R2 represents optionally substituted Ph, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen or 6 membered heteroaryl group containing 1 to 3 nitrogen atoms, processes for their preparation] were prepd as glycine antagonists. E.g., Et 7-chloro-4-(2-oxo-1-(4-

acetylamino)phenylpyrrolidin-3-ylidene)-1,2,3,4-tetrahydro-1-quinolinecarboxylate was prepared The affinity of I for the strychnine insensitive glycine binding site was determined The analgesic activity of I in mice was also determined

IT **252349-09-0P 252349-17-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydroquinoline derivs. as glycine antagonists)

RN 252349-09-0 CAPLUS
CN 2-Quinolinecarboxylic acid, 7-chloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt, (4Z)-(-)- (9CI) (CA INDEX NAME)

Rotation (-).
Double bond geometry as shown.



● Na

RN 252349-17-0 CAPLUS
CN 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>